Corvus Pharmaceuticals, Inc. (CRVS) stock
Close on Nov 11, 2026Market cap $964.87MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $964.87M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.63
- Dividend yield
- –
- Free cash flow yield
- -4.97%
Fundamentals
- Net income
- -$64.32M
- EPS, diluted
- -$0.71
- Free cash flow
- -$47.94M
- Book value per share
- $2.25
- Diluted shares
- 92M
Trading
- Next earnings
- Mar 11, 2027 (estimated, during market hours)
- Previous close
- $11.37
- Open
- $11.32
- Day's range
- $11.25 – $11.76
- Volume
- 822,126
- Average volume (20 days)
- 1,016,504
- Index membership
- Russell 2000 (since Jun 2025), Russell 3000 (since Aug 2025)
- Beta (5 years)
- 1.18
- 52-week range
- $6.39 – $26.95
- RSI (14 days)
- 58.1
- Volatility (1 year)
- 178.9%
- Relative volume
- 0.80×
- WACC
- 10.8%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CRVS | S&P 500 | Difference | CRVS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +9.0% | -2.4% | +11.4 pts | ||
| 3 months | -22.1% | -1.2% | −21.0 pts | ||
| Year to date | +49.0% | +12.3% | +36.7 pts | ||
| 1 year | +40.4% | +12.4% | +27.9 pts | ||
| 3 years | +725.2% | +78.8% | +646.4 pts | +102.1% | +21.4% |
| 5 years | +158.9% | +75.2% | +83.8 pts | +21.0% | +11.9% |
| 10 years | -28.1% | +311.1% | −339.2 pts | -3.2% | +15.2% |
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Corvus Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Update
About Corvus Pharmaceuticals
Pharmaceutical Preparations
The company is a clinical-stage biopharmaceutical enterprise focused on discovering and developing targeted therapies for immune-mediated diseases, inflammatory conditions, and cancers. Its research targets proteins critical to immune cell differentiation and function. The pipeline features soquelitinib, an oral covalent ITK inhibitor being evaluated in clinical studies for peripheral T-cell lymphomas and atopic dermatitis. Additional clinical-stage assets include ciforadenant, an adenosine A2A receptor antagonist under investigation for metastatic renal cell carcinoma, and mupadolimab, a B-cell-activating monoclonal antibody directed against CD73. Because the company does not operate commercial products, its programs address patient populations in specialized clinical trials.
Company profile, executives and historyCorvus Pharmaceuticals stock: common questions
What is Corvus Pharmaceuticals's stock price?
CRVS closed at $11.47 on Nov 11, 2026, up 0.88% on the day. Over the past 52 weeks it traded between $6.39 and $26.95.
What is Corvus Pharmaceuticals's market cap?
Corvus Pharmaceuticals was worth $964.87M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CRVS's P/E ratio?
Corvus Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.71), so it has no meaningful P/E ratio.
Does Corvus Pharmaceuticals pay a dividend?
No. Corvus Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Corvus Pharmaceuticals report earnings next?
Corvus Pharmaceuticals is expected to report Q4 FY2026 results on Mar 11, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has CRVS stock performed over the past year?
Including dividends, CRVS returned +40.4% over the past year, against +12.4% for the S&P 500.
How many CRVS shares are sold short?
18M shares were sold short at the latest FINRA report, 30.39% of the float, or 18.9 days of average trading volume.
Who are Corvus Pharmaceuticals's competitors?
Companies most similar to Corvus Pharmaceuticals by business, industry and size include RCUS, CNTX, ACRS, YARW, GRI.
See a number that looks wrong?